О. В. Благова

780 total citations
90 papers, 332 citations indexed

About

О. В. Благова is a scholar working on Cardiology and Cardiovascular Medicine, Infectious Diseases and Epidemiology. According to data from OpenAlex, О. В. Благова has authored 90 papers receiving a total of 332 indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Cardiology and Cardiovascular Medicine, 23 papers in Infectious Diseases and 18 papers in Epidemiology. Recurrent topics in О. В. Благова's work include Viral Infections and Immunology Research (52 papers), Cardiovascular Effects of Exercise (26 papers) and Cardiomyopathy and Myosin Studies (26 papers). О. В. Благова is often cited by papers focused on Viral Infections and Immunology Research (52 papers), Cardiovascular Effects of Exercise (26 papers) and Cardiomyopathy and Myosin Studies (26 papers). О. В. Благова collaborates with scholars based in Russia, United States and Romania. О. В. Благова's co-authors include Е А Коган, E. V. Zaklyazminskaya, В. В. Фомин, V. A. Sulimov, А. Е. Донников, Е. А. Мершина, Д. В. Калинин, В. Е. Синицын, Michał Tendera and Grigory Demyashkin and has published in prestigious journals such as SHILAP Revista de lepidopterología, European Heart Journal and European Journal of Immunology.

In The Last Decade

О. В. Благова

67 papers receiving 303 citations

Peers

Countries citing papers authored by О. В. Благова

Since Specialization

Citations

This map shows the geographic impact of О. В. Благова's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by О. В. Благова with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites О. В. Благова more than expected).

Fields of papers citing papers by О. В. Благова

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by О. В. Благова. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by О. В. Благова. The network helps show where О. В. Благова may publish in the future.

Co-authorship network of co-authors of О. В. Благова

This figure shows the co-authorship network connecting the top 25 collaborators of О. В. Благова. A scholar is included among the top collaborators of О. В. Благова based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with О. В. Благова. О. В. Благова is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Post-COVID Versus Non-COVID Myocarditis: Comparison of Morphological Activity, Toll-like Receptor Distribution and Responses to Immunosuppressive Therapy 2025 ·Frontiers in Bioscience-Scholar ·О. В. Благова, E. Kogan, (unknown), (unknown), (unknown)	0
2	Incidence and Impact of Myocarditis in Genetic Cardiomyopathies: Inflammation as a Potential Therapeutic Target 2025 ·Genes ·(unknown), E. V. Zaklyazminskaya, Е А Коган, (unknown), (unknown), О. В. Благова	1
3	COVID-19 in patients with primary cardiomyopathies: clinical course and outcomes, role of verified post-COVID myocarditis 2024 ·О. В. Благова, Е А Коган, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), E. V. Zaklyazminskaya	1
4	Hematologic mask of infective endocarditis as a cause of fever of unknown origin: a case report 2024 ·CARDIOVASCULAR THERAPY AND PREVENTION ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), О. В. Благова	0
5	Comparative Efficacy and Safety of Mycophenolate Mofetil and Azathioprine in Combination with Corticosteroids in the Treatment of Lymphocytic Myocarditis 2023 ·Journal of Clinical Medicine ·О. В. Благова, (unknown), Е А Коган, (unknown), (unknown)	3
6	Hypertrophic Cardiomyopathy Complicated by Post-COVID-19 Myopericarditis in Patient with ANO5-Related Distal Myopathy 2023 ·Genes ·О. В. Благова, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), E. V. Zaklyazminskaya, Е А Коган	0
7	Prevalence of myocarditis and its contribution to the course of primary myocardial hypertrophy 2023 ·SHILAP Revista de lepidopterología ·(unknown), О. В. Благова, Е А Коган, (unknown), (unknown), E. V. Zaklyazminskaya, Dzemeshkevich Sl	1
8	Prevalence of myocarditis, genetic cardiomyopathies and their combinations among patients of the Cardiology Hospital of the V.N. Vinogradov Faculty Therapeutic Clinic of the Sechenov University 2022 ·CARDIOVASCULAR THERAPY AND PREVENTION ·(unknown), (unknown), (unknown), (unknown), О. В. Благова, (unknown), (unknown), (unknown)	1
9	Infective and nonbacterial thrombotic endocarditis in patients with post-COVID-19 viral-immune myocarditis 2022 ·SHILAP Revista de lepidopterología ·О. В. Благова, (unknown), Е А Коган, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	3
10	Noncompact Myocardium with Dilated Phenotype: Manifestations, Treatment and Outcomes in Comparison with Other Forms of Dilated Cardiomyopathy Syndrome 2022 ·SHILAP Revista de lepidopterología ·О. В. Благова, (unknown), (unknown), (unknown), (unknown), Е. А. Мершина, (unknown), E. V. Zaklyazminskaya, (unknown)	0
11	Comparative efficacy and safety of mycophenolate mofetil and azathioprine in combination with corticosteroids in the treatment of lymphocytic myocarditis 2021 ·SHILAP Revista de lepidopterología ·(unknown), О. В. Благова, Е А Коган, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), А. Е. Донников, (unknown)	1
12	Subacute and chronic post-covid myoendocarditis: clinical presentation, role of coronavirus persistence and autoimmune mechanisms 2021 ·Kardiologiia ·О. В. Благова, Е А Коган, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), В. В. Фомин	18
13	Myocarditis: diagnosis and treatment in a period of pandemic 2021 ·SHILAP Revista de lepidopterología ·О. В. Благова, Е А Коган	1
14	Myocardial morphological changes and pulmonary vein catheter ablation efficacy in patients with atrial fibrillation 2021 ·SHILAP Revista de lepidopterología ·(unknown), К. V. Davtyan, О. В. Благова, (unknown), (unknown), М. С. Харлап, (unknown)	0
15	Contribution of concomitant myocarditis to the development of various clinical types of arrhythmogenic right ventricular cardiomyopathy 2021 ·SHILAP Revista de lepidopterología ·(unknown), О. В. Благова, (unknown), (unknown), (unknown), (unknown), E. V. Zaklyazminskaya	2
16	Spectrum of desmosomal gene variations in patients with arrhythmogenic right ventricular cardiomyopathy 2021 ·SHILAP Revista de lepidopterología ·(unknown), О. В. Благова, (unknown), Dzemeshkevich Sl, E. V. Zaklyazminskaya	1
17	Miocarditis in Patients with COVID-19 Confirmed by Immunohistochemical 2020 ·Kardiologiia ·Е А Коган, (unknown), О. В. Благова, (unknown), (unknown), (unknown), Д. В. Калинин, (unknown), (unknown), (unknown), (unknown), В. В. Фомин	26
18	Myocarditis in right ventricular arrhythmogenic dysplasia/cardiomyopathy: frequency, role in phenotype development, results of treatment 2020 ·О. В. Благова, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), А. Е. Донников, (unknown), E. V. Zaklyazminskaya	3
19	INDICATIONS FOR IMPLANTATION AND EFFICIENCY OF CARDIOVERTER-DEFIBRILLATORS IN PATIENTS WITH DILATED CARDIOMYOPATHY 2019 ·(unknown), О. В. Благова, (unknown), (unknown), E. V. Zaklyazminskaya	1
20	Massive tuberculous exudative pericarditis under the guise of hydropericardium in a patient with non-compaction cardiomyopathy: diagnosis and treatment 2019 ·SHILAP Revista de lepidopterología ·О. В. Благова, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact